

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM


FACSIMILE TRANSMISSION**DATE:** April 24, 2003**MATTER NUMBER:** 10107932

RECIPIENT:	FAX NO.:	PHONE NO.:
Gerald G. Leffers, Jr.	703-305-7939	

FROM: Steven L. Highlander **USER ID:** SH01973 **FLOOR:** 20**PHONE:** (512) 536-3184 **FAX:** (512) 536-4598**Re:** Serial No. 09/612,809**NUMBER OF PAGES WITH COVER PAGE:** 1 S Originals Will Not Follow**Message:****CERTIFICATE OF FACSIMILE TRANSMISSION**
37 C.F.R. § 1.8

I hereby certify that this correspondence is being transmitted to: Commissioner for Patents, Washington, D.C. 20231, Attn: Examiner Gerald G. Leffers, Jr., GAU 1636, facsimile number (703) 305-7939 on the date below.

April 24, 2003
Date


Steven L. Highlander**CAUTION - CONFIDENTIAL**

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU.

**IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL
AT AS SOON AS POSSIBLE.**


FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIABILITY PARTNERSHIP
 600 CONGRESS AVENUE, SUITE 2400
 AUSTIN, TEXAS 78701-3271
 WWW.FULBRIGHT.COM

SHIGHLANDER@FULBRIGHT.COM
 PARTNER
 DIRECT DIAL: (512) 536-3184

TELEPHONE: (512) 474-5201
 FACSIMILE: (512) 330-4598

April 24, 2003

CERTIFICATE OF FACSIMILE TRANSMISSION <i>37 C.F.R. § 1.8</i>	
<p>I hereby certify that this correspondence is being transmitted to: Commissioner for Patents, Washington, D.C. 20231, Attn: Examiner Gerald G. Leffers, Jr., GAI 1636, facsimile number (703) 305-7939 on the date below:</p>	
<u>April 24, 2003</u> <i>Date</i>	 <i>Steven L. Highlander</i>

Commissioner for Patents
 Washington, DC 20231

Re: Serial Number 09/612,809 entitled "THERAPEUTICS AND DIAGNOSTICS FOR CONGENITAL HEART DISEASE BASED ON A NOVEL HUMAN TRANSCRIPTION FACTOR" by Val C. Sheffield et al.
Our ref: IOWA:042USD1; Matter No. 10107932

Commissioner:

Enclosed for filing in the above-referenced patent application is:

1. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Dated April 18, 2003.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50 1212/IOWA:042USD1.

Very truly yours,


Steven L. Highlander

SLH/cpj
 Encl: As noted

25284836.1



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO/ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR/ PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
--------------------------------	-------------	--	---------------------

EXAMINER

Gerald G. Leffers Jr.

ART UNIT	PAPER
----------	-------

1636 18

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

The communication filed 2/4/03 is not fully responsive to the Office communication mailed 12/31/02 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CFR Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 – 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the reply appears to a bona fide attempt to comply with the requirements of the sequence rules (37 CFR 1.821 – 1.825), applicant is given a **TIME PERIOD of ONE (1) MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 – 1.825) in order to avoid abandonment of the application under 37 CFR 1.821 (g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner **Gerald G. Leffers Jr.**, Art Unit 1636, whose telephone number is (703) 308-6232.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Remy Yucel** can be reached at (703) 305-1998. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application, or relating to attachments to this office action, should be directed to the Patent Analyst **Zeta Adams**, whose telephone number is (703) 305-3291.

Gerald G. Leffers Jr.
Gerald G. Leffers Jr., PhD.
Examiner, Art Unit 1636


FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-9201
FACSIMILE: (512) 536-4598

January 30, 2003

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: U.S. Patent And Trademark Office, Box Sequence Listing, P.O. Box 2327, Arlington, VA 22202, on the date below:	
<u>January 30, 2003</u> Date	 Steven L. Highlander

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Re: *U.S. Patent Application Serial No. 09/612,809 Entitled: "THERAPEUTICS AND DIAGNOSTICS FOR CONGENITAL HEART DISEASE BASED ON A NOVEL HUMAN TRANSCRIPTION FACTOR" – Val C. Sheffield et al.*
Our Ref. No. IOWA:042USD1; Matter No. 10107932

Commissioner:

Enclosed for filing in the above-referenced patent application is:


1. Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.
2. Response to Notice to Comply with Requirement for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Dated December 31, 2002;
3. Statement As Required Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required Under 37 C.F.R. § 1.821(g); Substitute Computer Readable Form (Diskette); a Substitute Paper Copy; and
4. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

25257722.1

Commissioner For Patents
January 30, 2003
Page 2

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/IOWA:042USD1.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/cpj

Encl.:

Commissioner For Patents

January 30, 2003

Page 3

Bcc: Daniel G. Happe, Esq. (w/encl.)
W. Bruce Wheaton, Ph.D. (w/encl.)
Val C. Sheffield, Ph.D. (w/encl.) for distribution to:
Wallace L. M. Alward, Ph.D. (w/encl.)
Shiva Patil, Ph.D. (w/encl.)
Edwin M. Stone, Ph.D. (w/encl.)
Darryl Nishimura, Ph.D. (w/encl.)

Please indicate receipt of the below-identified paper:

Priority Date:

Please indicate receipt of the below-identified paper:				
Priority Date:				
<input type="checkbox"/> New Application For:				
<input type="checkbox"/> Foreign priority already claimed				
<input type="checkbox"/> Continuation	<input type="checkbox"/> CIP	<input type="checkbox"/> Divisional	CPA	<input type="checkbox"/>
<input type="checkbox"/> Specification:	Pages	<input type="checkbox"/> Drawings:	Sheets	
<input checked="" type="checkbox"/> Response to Office Action Dated: 09/27/02		<input type="checkbox"/> Final Rejection		
<input checked="" type="checkbox"/> Other TRANSMITTAL LTR.; NOT TO COMPLY; RESPONSE TO NOT TO COMPLY; STATEMENT AS REQ.; SUB. COMP. READABLE FORM; DISKETTE; SUB. PAPER COPY AND RETURN POSTCARD		<input checked="" type="checkbox"/> VPK 60 60		
<input type="checkbox"/> Assignment Enclosed	<input checked="" type="checkbox"/> Cert. of Timely Mailing	<input type="checkbox"/> Exp. Mail:		
IDENTIFICATION OF APPLICATION				
FEB 04 2003				

Serial No.:	09/612,809
Title: THERAPEUTICS AND DIAGNOSTICS FOR CONGENITAL HEART DISEASE BASED ON A NOVEL GAUNIAN TRANSCRIPTION FACTOR	
Attorney:	S.H.I.
F&J File No.:	IOWA:042USD1
Due Date:	
Client:	UNIVERSITY OF IOWA RESEARCH FOUNDATION
Mailed:	Filed: 01/30/03